AKRO – akero therapeutics, inc. (US:NASDAQ)

Akero Therapeutics: A Promising Solution For NASH Patients And Investors [Seeking Alpha]

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target lowered by analysts at HC Wainwright from $64.00 to $62.00.

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Akero Therapeutics: Proof Of Concept With EFX, Sets Up Catalyst Opportunities In 2023 [Seeking Alpha]

Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $58.00. They now have a "buy" rating on the stock.

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results